
    
      The purpose of this prospective, non-interventional study is to perform neurological and
      cognitive assessment of breast cancer patients who receive standard of care single agent
      weekly paclitaxel or docetaxel chemotherapy to determine the onset and severity of
      chemotherapy induced neuropathy (CIPN) and cognitive impairment (CICI).
    
  